Bain Capital

Bain Capital, established in 1984, is a global multi-asset alternative investment firm with over $100 billion in assets under management. Headquartered in Boston, Massachusetts, the firm operates through several business units: Private Equity, Public Equity, Credit, and Venture Capital. Bain Capital Private Equity invests in various sectors, including consumer, healthcare, industrials, and technology, across North America, Europe, and Asia. Bain Capital Ventures, the venture capital arm, focuses on seed to growth-stage investments in enterprise software, infrastructure software, and industries being transformed by data. Bain Capital Life Sciences, a dedicated life sciences investment platform, invests in biopharmaceutical, specialty pharmaceutical, medical device, diagnostics, and enabling life science technology companies globally. Bain Capital Double Impact, the firm's impact investing arm, builds great companies that deliver both competitive financial returns and meaningful, measurable social and environmental good.

Darren Abrahamson

Managing Director

Ajay Agarwal

Managing Director

Marc Akinbi

Associate

Thomas Allen

Principal

Eric Anderson

Managing Director and Member of the North American Private Equity Team

Maria Andrisani

Investor

Ernesto Anguilla

Managing Director

Tim Anten

Managing Director and Member of the European Private Equity Team

Melaku Arega

Associate

Carlos Argilagos

Investor

Emily Ashworth

Managing Director, Operating Partner of Portfolio Group and Member of the North American Private Equity team

Dewey Awad

Managing Director

Brad Balter

Vice President

Lorenzo Bartolini

Associate

James Bath

Vice President

Cecile Belaman

Managing Director

Jonathan Belitsos

Principal

Nicholas Bendt

Principal

Saahil Bhatia

Principal

Bruce Biegler

Associate

William Bihrle

Principal

Riker Bixby

Associate

Brooks Blake

Investment Director and Partner, Investments

Andrew Brady

Associate

Allison Braley

Partner

Devon Breton-Pakozdi

Associate

Jakob Brevinge

Principal

Andrej Busch

Managing Director

Giovanni Camera

Principal

Matt Cannan

Managing Director

Edgar Carrero

Associate

Phillip Carter

Managing Director

Jonah Cashdan

Vice President

Hui Chan

Principal

Amit Chandra

Managing Director

Hunter Chang

Associate

Cecilia Chao

Managing Director

Owen Chapey

Associate

Brad Charchut

Managing Director

Daniel Charnoff

Vice President

Shuvam Chaudhuri

Associate

Daisy Chen

Principal

Drew Chen

Managing Director

Mary Chen

Associate

Leong Cheung

Operating Partner

John Paul (JP) Chilazi

Principal

Mike Choi

Principal

Kevin Chong

Partner, Special Situations and Head of Special Situations Portfolio Group

Kei W. Chua

Managing Director

Tan Chuqiao

Partner

Davis Clayson Jr.

Managing Director

Alysaa Co

Vice President

Alysaa Co

Associate

Stefan Cohen

Partner

Zeeza Cole

Investor

Amanda Conklin

Vice President, Double Impact

John Connaughton

Managing Partner

Todd Cook

Partner

Michael Cooney

Associate

Jay Corrigan

Group Co-CFO

Ryan Cotton

Managing Director

Pascal Croak

Investor

Leslie Crowe

Partner

Frank D'Hollander

Operating Partner

Jennie Daisak

Associate

Jennifer Davis

Partner, Private Equity, Consumer and Retail Vertical and Member of the North American Private Equity Team

Nathaniel Denby

Associate

Clarence Deng

Vice President

David DesPrez

Managing Director

Wayne Deveydt

Managing Director and Member of Portfolio Group for North America Private Equity

Tina Dimitrova

Principal

Sara Diniz

Investor

Christina Dix

Partner, Healthcare Vertical and Member of European Private Equity team

Arnaud Doerane

Principal

Jacob Donnelly

Partner

David Edelson

Managing Director of Portfolio Group and Member of the North American Private Equity

Erin Endres

Associate

Eric Erb

Managing Director

Matt Evans

Managing Director

Liraz Evenor

Managing Director Private Equity and Director in the Consumer and Retail Vertical & Member of the Portfolio Group for North America Private Equity

Andy Fan

Principal

Robert Farkas

Partner, Private Equity and Member of the North American Private Equity Team

Leonard Feiner

Principal

Clark Feng

Managing Director

Valentin Fernandez

Vice President

Drew Field

Associate

Daniel Fishbaum

Investor

Jorge Fournier

Associate

Matt Freeman

Managing Director

Michel Freund

Partner and Member of the North American Private Equity Team

Scott Friend

Managing Partner

Rak Garg

Partner

Nick Gattas

Vice President

Francois Gilbart

Operating Partner, Private Equity

James Goldman

Investor

Brian Goldsmith

Principal

Dylan Goldstein

Associate

Nikolay Golubev

Managing Director

Ben Gottdiener

Associate

Michael Grandfield

Partner

Jeffrey Green MD

Partner

Evan Greif

Associate

Max de Groen

Managing Director

David Gross-Loh

Managing Director

Kevin Guan

Principal

Andrew Hack

Managing Director

Soren Haefcke

Principal

Dave Hamilton

Partner and Co-Head of Information Technology

Ingrid Hammond

Vice President

Kristie Han

Principal

Kim Harris

Managing Director

Matthew Harris

Partner

Alena Harrison

Vice President

Joshua Hartz

Managing Director

Ray Hass

Managing Director and Member of the Asia Pacific Portfolio Group

Dawit Heck

Principal

Blair Hendrix

Managing Director

Darren Herman

Managing Director, Private Equity and Member of the North American Private Equity team

Rachel Hersh

Associate

Aaref Hilaly

Partner

Jim Hildebrandt

Managing Director

Sarah Hinkfuss

Partner

Alex Hocherman

Managing Director

Alison Holmes

Principal, Private Equity and Consumer, Retail and Dining Vertical & Member of the North American Private Equity Team

Hajime Honda

Principal

Halvor Meyer Horten

Managing Director

Olivia Howard

Managing Director

Catherine Hua

Associate

June Huang

Vice President

Merritt Hummer

Partner

David Humphrey

Managing Director

Jonathan Humphrey

Principal

Viva Hyatt

Managing Director

Abhiroop Jayanthi

Principal

Sue Jia

Associate

Cristian Jitianu

Managing Director

Philippe Kamel

Vice President

Masafumi Kamishiro

Vice President

Andrew Kaplan

Partner, Private Equity and Healthcare Vertical and Member Of The North American Private Equity Team

Christopher Kastner

Managing Director, Portfolio Group and Member of the North American Private Equity team

Andrew Kateiva

Managing Director

Nick Kazarinoff

Vice President

James Kellog

Managing Director

Liam Kennedy

Partner and Corporate Controller

Kevin Kerby

Managing Director, Private Equity and Member of the North American Private Equity Team

Victoria Khanna

Managing Director

Tomohiro Kikuta

Managing Director

Daniel Kim

Principal

Hyunseung Kim

Vice President

Ryuto Kobayashi

Managing Director

Klaus Koenigshausen

Principal

Takatoshi Kojima

Vice President

Hayato Kondoh

Vice President

Adam Koppel

Managing Director

Joshua de Kroes

Vice President

Mike Krupka

Partner

Hisashi Kubodera

Principal and Member of the Asian Pacific Private Equity Team

Ajay Kumar

Principal

Christina Kyriazi

Partner

Komi Kyu

Principal

Charles Lawson

Principal

Max Lechtman

Analyst

Chris Leddy

Principal

Jungwoo Lee

Managing Director

Casey Leonetti Ph.D

Managing Director, Private Equity

Adam Levin

Partner

Susan Levine

Managing Director

Carolyn Liu

Managing Director

Andrew Liu

Vice President

Zihan Liu

Vice President

Angela Liu

Associate

Cara Lorion

Managing Director, Partner and Co-CFO for Coinvest, GP and Partner Services

Phillip Loughlin

Partner, Global Head of the Financial and Business Services Vertical and Member of the Consumer / Retail Vertical

Phil Loughlin

Managing Director

Benjamin Lund

Principal

James Mackey

Principal, Private Equity and Technology Vertical and Member of the North American Private Equity Team

Ritika Mahal

Vice President

Rishi Mandawat

Managing Director

Vibhu Manya

Operating Partner, Private Equity and Member of the Asian Pacific Private Equity Team

Francesco Marra

Vice President

Giacomo Massetti

Managing Director, Consumer and Industrial Verticals and Member of the European Private Equity team

Kimberly McCaslin

Partner, Private Equity and Head of the North America Portfolio Group

Christina (Phillips) Melas-Kyriazi

Partner

Christophe Jacobs van Merlen

Managing Director

Greg Mervine

Associate

Abby Meyers

Principal

Grace Mollard

Principal

Sarah Morris

Managing Director of Portfolio Group and Member of the European Private Equity Team

Frank Morton

Associate

Paul Moskowitz

Principal

Colin Motley

Managing Director, Technology, Media, Telecom Vertical and Private Equity and Member Of The North American Private Equity Team

Michael Murphy

Partner, Private Equity

Maurizio Mussi

Managing Director

Shunsuke Nakahama

Managing Director

Cara Nealon

Senior Vice President, Portfolio Group and Member of the North American Private Equity Team

Adam Nebesar

Managing Director

Brandon Nishida

Associate

Petr Nosek

Principal

Ethan O'Neill

Associate

Devin O'Reilly

Managing Director

Kazunari Obama

Vice President

Martha Obasi

Vice President

Yurio Ogawa

Managing Director

Saanya Ojha

Partner

Fatima Porras Olalla

Vice President

Nicholas Onie

Vice President

Mohaira Osman

Associate

Kenichi Ota

Principal

Kohei Otani

Vice President

Jeff Otis

Operating Partner, Private Equity and Portfolio Group and Member Of The North American Private Equity Team

Stephen Pagliuca

Managing Director

Jie Pan

Operating Partner

Minju Park

Vice President

Hardi Patel

Associate

Sandro Patti

Investor

Sam Payne

Vice President

Gregory Petros

Principal, Healthcare Vertical and Member of the European Private Equity team

Josh Plavner

Principal

Matt Popoli

Investor

Benjamin Prawdzik

Vice President, Consumer and Financial and Business Services Verticals

Marc Pulde

Vice President

Chen Qian

Principal

Larissa Quinn

Vice President

Gianni Renzi

Associate

Peter Riehl

Managing Director

Allyson Rinderle

Managing Director

Allyson S. Rinderle

Managing Director

Steve Rizoli

Principal

Joseph Robbins

Managing Director

Mitt Romney

Founder

Joshua Ross

Managing Director

Douglas Rudisch

Managing Director

Ali Rundlett

Investor

Mark Saadine

Principal

Jeremie Saiman

Vice President

Enrique Salem

Managing Partner

Youssef Salha

Principal

Linas Samuolis

Investor

Tom Sargeant

Managing Director

Jeff Scherer

Managing Partner

Quinn Schwab

Vice President

Jeffrey Schwartz

Managing Director

Matt Sears

Principal

Dominik Seitz

Principal

Ivano Sessa

Managing Director

Hajime Shimazu

Principal

Jacob Silverman

Associate

Harry Simpson

Vice President

Ari Singer-Freeman

Associate

Pavninder Singh

Managing Director

David Spiller JD

Partner of Portfolio Group and Member of the North American Private Equity Team

Peter Spring

Managing Director

David Steiner

Vice President of Real Esate

Kate Steinman

Associate

James Stevens

Principal

Slater Stich

Partner

Zhao Su

Principal

Pooja Subramaniam

Associate

Radhika Subramanian

Principal, Consumer, Retail and Financial services and a Member of the Asia Pacific Private Equity team

Masa Suekane

Managing Director

Ricky Lijing Sun

Managing Director

Mark Sutton

Chief Information Security Officer and Managing Director

Junichi Takami

Vice President

Yuji Takei

Managing Director

James Tam

Managing Director

Will Tetler

Principal

Ellinor Thiel

Vice President

Aurelia Tichoux

Vice President

Miray Topay

Managing Director

John Toussaint

Managing Director

Pierre-Henri Vacher-Lavenu

Vice President

William Van Fossen

Associate

Davide Vidotto

Vice President

Paolo Vismara

Managing Director, Portfolio Group and Member of the European Private Equity team

Shunsuke Wakita

Vice President

Nigel Walder

Managing Director

Stephanie Walsh

Managing Director

Renjie Wang

Principal

Danielle Wang

Vice President

Florence Wang

Investor

Michael Ward

Managing Director, COO and CFO

Iain Ware

Managing Director

Shun Watanabe

Vice President

Harris Weber

Vice President

Sam Weil

Vice President

Lauren Weishaar

Investor

James Weldon

Associate

Radhesh Welling

CEO

Phil Wieland

Operating Partner

Jeff Williams

Operating Partner

Shena Willis

Vice President

ELi Winkler

Vice President

Patricia Winton

Partner and Head of ESG

John Wright

Managing Director

Natalie Wright

Partner and Head of Investment Operations, Private Equity

Ray Xi

Principal

Frank Yao

Managing Director

Takumi Yoshikawa

Partner

Martina Yu

Vice President

Amanda Zajac

Investor

Kevin Zhang

Partner

Lina Zhou

Vice President

Jason Zhu

Principal

Jonathan Jia Zhu

Managing Director

Jack Zhu

Vice President

Paul Zurlo

Partner

Jack Sun

Principal

Maren Hopkins

Vice President

Zhenyu Zhang Ph.D

Managing Director and Member of the Asian Pacific Private Equity Team

Amir Zamani

Principal

R.J Cunio

Associate

Charles Megaw Ph.D

Partner, Private Equity and Member of Portfolio Group for Europe Private Equity

Will Cozean

Managing Director

1006 past transactions

Astronomer

Series D in 2025
Astronomer, Inc. is a company based in Cincinnati, Ohio, that specializes in developing a managed platform for data orchestration, primarily utilizing Apache Airflow. Established in 2014, Astronomer offers a comprehensive suite of products and services through its platform, known as Astro. This platform is designed to streamline the process of building, running, and monitoring data pipelines-as-code, catering to the needs of data engineers, scientists, and analysts. By providing tools for deploying, managing, and scaling data workflows, Astronomer enhances the availability of trusted data for organizations, making it easier for data teams to conduct business analytics effectively. As a commercial developer of Airflow, Astronomer plays a significant role in the data orchestration landscape, serving hundreds of thousands of teams globally.

Structify

Seed Round in 2025
Structify is a technology company that specializes in data extraction and structuring. It offers a platform that enables businesses to create custom datasets by specifying the data format, selecting the source(s), and assigning agents to search and extract the data. The company's in-house model ensures the quality and accuracy of the extracted data across various use cases. Structify has found applications in finance, construction, and corporate technology, helping teams extract and organize data from diverse sources such as pitch decks, geotechnical documents, and real-time chain of command data.

Navro

Series B in 2025
Navro is a fintech platform that provides payment and banking infrastructure for software companies to scale their operations globally. It offers a regulated network that curates payment options, enables checkout in preferred methods, connects various payment acceptance methods, collects funds locally, and provides payment stack management with real-time local coverage, supporting international growth while maintaining regulatory compliance.

BitradeX

Series A in 2025
BitradeX is a technology company specializing in digital asset trading. It operates an AI-powered trading platform that leverages innovative algorithms and blockchain technology to enhance the trading experience. The platform offers intelligent automation, robust compliance measures, and a user-centric design, aiming to provide a secure, efficient, and intelligent trading ecosystem for its users.

Lincoln Financial Group

Post in 2025
Lincoln Financial Group is a Fortune 500 insurance and financial services company based in Radnor, Pennsylvania, established in 1905 with the endorsement of Robert Todd Lincoln, the son of Abraham Lincoln. The company is dedicated to providing a wide range of products, including life insurance, annuities, retirement plan services, and group protection. It focuses on wealth protection, accumulation, and retirement income solutions, aiming to help individuals secure better futures for themselves and their families. With over a century of experience, Lincoln Financial Group has built its reputation on the principles and ideals associated with Abraham Lincoln, emphasizing honesty and dependability in its financial services.

Sizzling Platter

Acquisition in 2025
Sizzling Platter, LLC is a food and beverage company that owns and manages a diverse portfolio of fast casual restaurants in the United States and internationally. Founded in 1963 and headquartered in Murray, Utah, the company offers a variety of menu items, including pizzas, donuts, coffee, burgers, steak, seafood, and salads, catering to a wide range of tastes. Sizzling Platter focuses on acquiring and supporting restaurant brands, providing them with resources for growth and financial success. The company also emphasizes social responsibility by donating food to those in need on designated days. Through its commitment to delivering exceptional dining experiences and supporting its brand partners, Sizzling Platter aims to establish itself as a leading franchise platform in the food service industry.

Merida Biosciences

Series A in 2025
Merida Biosciences is a biotechnology company specializing in the development of precision therapies for autoimmune diseases. It employs a protein engineering platform to create novel Fc therapeutics, which selectively target and neutralize specific antibodies, aiming to treat the root cause of antibody-driven diseases with high precision and durability.

HealthEdge Software

Acquisition in 2025
HealthEdge provides a modern suite of products, HealthRules, built on patented technology. It enables healthcare payors to innovate, reduce costs, and improve outcomes by connecting everyone in the healthcare delivery cycle.

KREA

Series B in 2025
KREA is an artificial intelligence platform that lets users generate images from text prompts and organize them into collections. It enables training a personalized AI using a user’s own images to tailor the model to individual style, and it provides access to millions of AI-generated images to inspire projects.

Atsena Therapeutics

Series C in 2025
Atsena Therapeutics is a clinical-stage company focused on developing gene therapies for inherited retinal diseases. Utilizing an adeno-associated virus (AAV) platform, including a novel spreading capsid, Atsena's clinical programs aim to prevent blindness caused by genetic mutations.

Actively AI

Series A in 2025
Actively AI is a technology company founded by researchers from Stanford University, specializing in an artificial intelligence-based outbound sales platform. The company aims to enhance lead generation and prospecting efficiency for sales teams by offering features such as automated account research and real-time identification of top prospects. Additionally, Actively AI provides personalized messaging generation based on data insights, which enables organizations to significantly increase their sales pipeline and improve meeting booking rates. By streamlining these processes, the platform allows sales representatives to concentrate on engaging with potential clients, ultimately driving better sales outcomes.

LightSource

Series A in 2025
LightSource develops a supply chain management platform to help professionals collaborate with their suppliers. It also allows collaborating with teammates on strategic sourcing projects, sending RFQs to suppliers and collecting quotes, and comparing bids using insights automatically extracted from the normal day-to-day work. The company was founded in 2021 and is headquartered in San Francisco, California.

Straiker

Series A in 2025
Straiker is a technology company that specializes in AI-native security solutions. It develops AI risk assessment software to enhance security through one-time or continuous testing. The company's technology simulates attacks against AI applications and agents, conducting a suite of security checks to identify and mitigate critical AI risks, providing protection beyond prompt-level threats and enabling automated threat blocking.

Namirial

Acquisition in 2025
Namirial is a developer of digital transaction management software that facilitates the complete digital transformation of business processes for private sector companies and public administration organizations. The company's platform encompasses a range of services, including identity management, electronic signatures, certified communication, document management, electronic invoicing, and cybersecurity. By integrating these solutions, Namirial enables organizations to efficiently manage and execute both internal and external document-centric transactions in a fully digital environment, enhancing operational efficiency and security.

HeartFlow

Convertible Note in 2025
HeartFlow specializes in precision heart care, offering a non-invasive solution for diagnosing coronary artery disease. Its proprietary HeartFlow FFRCT Analysis uses artificial intelligence to create a personalized 3D model of the heart, enabling clinicians to evaluate blood flow and determine optimal treatment. Commercially available in the United States, UK, Canada, Europe, and Japan.

Silna Health

Series A in 2025
Silna Health specializes in streamlining healthcare processes by offering a proactive care readiness platform. This platform ensures patients are eligible for care and handles prior authorizations, benefit checks, and insurance monitoring, thereby enhancing payment certainty and improving patient outcomes. It enables healthcare providers to expedite the process of scheduling appointments, from initial inquiry to booking, by managing these administrative tasks upfront.

Manappuram Finance

Post in 2025
Manappuram Finance is an Indian non-banking financial company that provides a range of retail credit and financial services. It offers gold loans secured by pledging household and used gold jewelry, microfinance, housing loans, vehicle and SME loans, and loans against property. It also provides ancillary services such as life and non-life insurance products, IT services, depository services, pan card services, and money transfer and foreign exchange facilities. The company operates through a nationwide branch network across India and targets low- and middle-income borrowers. It was founded in 1949 and is headquartered in Thrissur, Kerala.

Norm AI

Series B in 2025
Norm AI is a developer of an AI-powered regulatory compliance platform tailored for the legal and compliance sectors. The company's innovative approach addresses the regulatory sludge problem by transforming complex regulations into autonomous AI agents capable of making compliance determinations. This platform allows compliance teams to delegate tasks to these regulatory AI agents through high-level instructions, ensuring that the resulting work product is validated at various levels of detail. Norm AI's solutions enhance efficiency and accuracy in compliance processes, significantly benefiting organizations navigating intricate regulatory landscapes.

CMIC Holdings

Acquisition in 2025
CMIC Holdings is a Japan-based company founded in 1992 and headquartered in Minato-ku, Tokyo. It operates primarily as a contract research organization (CRO) and offers a diverse range of services tailored to the pharmaceutical and healthcare sectors. These services include contract development and manufacturing (CDMO), contract sales organization (CSO) support, and innovative pharmaceutical models (IPM). CMIC specializes in various aspects of pharmaceutical management, encompassing data management, statistical analysis, medical consulting, medical writing, auditing, and analytical testing. Additionally, the company plays a vital role in facilitating clinical trials and providing human resource services, as well as sales and marketing support, thereby contributing significantly to advancements in medical and healthcare fields.

Charta

Seed Round in 2025
Charta Health is a technology company specializing in medical billing optimization. It employs artificial intelligence to scrutinize patient charts before claims are submitted, ensuring all potential revenue opportunities are captured, claim denials are minimized, and billing standards are consistently met. The platform offers real-time analytics, audits, and autonomous chart reviews, empowering healthcare professionals to enhance administrative efficiency and patient care.

Surf Internet

Private Equity Round in 2025
Surf Internet specializes in fiber optic and wireless broadband services for residential customers, businesses, educational institutions, and municipalities across Indiana, Illinois, and Michigan. It offers high-speed internet plans tailored to diverse usage needs, ensuring reliable connectivity for activities like streaming, gaming, and remote work. The company focuses on expanding its network infrastructure to improve service availability and performance, accompanied by dedicated customer support.

Hightouch

Series C in 2025
Hightouch is a customer data platform that specializes in data synchronization between various marketing and operational tools. The company enables businesses to connect their existing data warehouses with applications such as customer relationship management systems, email marketing platforms, and advertising networks. By providing a user-friendly interface, Hightouch simplifies data integration and management, allowing organizations to access and utilize their data effectively without duplication. This approach helps maintain data integrity and security, while empowering clients to leverage their data for personalized marketing campaigns. Hightouch's platform features audience segmentation, data transformation, and automated workflows, which assist businesses in optimizing their marketing strategies and operational processes.

Solid Biosciences

Post in 2025
Solid Biosciences Inc. is a life science company focused on developing therapies for Duchenne muscular dystrophy (DMD), a genetic muscle-wasting disease primarily affecting boys. The company's lead product candidate, SGT-001, is a gene transfer therapy currently undergoing a Phase I/II clinical trial aimed at restoring functional dystrophin protein expression in patients' muscles. In addition to SGT-001, Solid Biosciences is advancing the Anti-LTBP4 program, which involves a monoclonal antibody designed to reduce fibrosis and inflammation by targeting the LTBP4 protein. The company also develops biomarkers and sensors, as well as the Solid Suit program, which focuses on creating wearable assistive devices with functional and therapeutic benefits. Founded in 2013 and headquartered in Cambridge, Massachusetts, Solid Biosciences has established a strategic collaboration with Ultragenyx to enhance gene therapy development for DMD. With no current cure for DMD, the company aims to provide innovative solutions for a condition that affects an estimated 10,000 to 15,000 cases in the United States.

Dream Security

Series B in 2025
Dream Security is a cybersecurity company that develops AI solutions to protect against cyber threats. The company provides various cybersecurity services, including AI-driven threat detection to monitor network activity for anomalies, incident response teams to manage and analyze cyber incidents, and vulnerability management through regular assessments and penetration testing. They also offer security awareness training, assist with compliance and risk management to meet regulatory requirements, and provide cloud security solutions for cloud infrastructures. Additionally, the company offers consulting services to help organizations develop and implement cybersecurity strategies.

Apleona

Acquisition in 2025
Founded in 2016, Apleona is a leading provider of integrated real estate services in the DACH region. It offers a comprehensive range of services including facility management, building technology, interior fittings, and real-estate management with commercial services such as letting, leasing, and marketing.

Abcuro

Series C in 2025
Abcuro, Inc. is a biotechnology company focused on developing immunotherapies for the treatment of autoimmunity and cancer. Established in 2015 and headquartered in Newton, Massachusetts, Abcuro specializes in creating therapeutic antibodies that target novel pathways in these diseases. The company employs advanced bioinformatics to analyze transcription data from human diseases, enabling them to identify new therapeutic targets within the immune system. By leveraging clinical insights and systematic target validation, Abcuro aims to develop immune-modulatory biotherapeutics that provide innovative treatment options for patients suffering from autoimmune disorders and cancer.

Index

Seed Round in 2025
The product-native discovery companion for Linear. Collect feedback, brainstorm ideas, and manage product plans.

SelectQuote

Post in 2025
SelectQuote Insurance Services, Inc. is an insurance company based in San Francisco, California, specializing in a diverse array of insurance products, including term life, auto, home, and Medicare insurance. Founded in 1985, SelectQuote aims to assist families by providing tailored insurance solutions that meet their specific needs and budget. Operating as a subsidiary of SelectQuote, Inc., the company utilizes a direct-to-consumer distribution model, allowing clients to compare rates from a wide range of highly rated insurance providers online. This approach ensures that consumers receive the best possible coverage at competitive prices. SelectQuote generates revenue through commissions earned by selling insurance products on behalf of its carrier partners and operates through four key segments: Senior, Healthcare Services, Life, and Auto & Home.

Mitsubishi Tanabe Pharma

Acquisition in 2025
Mitsubishi Tanabe Pharma is a Japanese pharmaceutical company that develops and manufactures drugs for various indications, including immuno-inflammation, diabetes and kidney diseases, central nervous system disorders, vaccines, and over-the-counter products. Its portfolio includes Simponi for rheumatoid arthritis, Invokana for type 2 diabetes mellitus, Stelara for Crohn’s disease, Radicava for amyotrophic lateral sclerosis, Gilenya for multiple sclerosis, and Remicade for inflammatory autoimmune diseases. The company also offers vaccines such as influenza vaccine and Varicella vaccine.

Milacron Holdings

Acquisition in 2025
Milacron Holdings is a prominent manufacturer and distributor of highly engineered and customized systems within the plastic technology and processing industry, which is valued at approximately $27 billion. The company offers a comprehensive product portfolio that includes injection molding, blow molding, extrusion equipment, and hot runner systems, positioning itself as the only global entity with such a full-line offering. Milacron's operations are divided into three segments: Advanced Plastic Processing Technologies, Melt Delivery and Control Systems, and Fluid Technologies. The Advanced Plastic Processing Technologies segment focuses on the design and manufacture of various molding equipment and related services, while the Melt Delivery and Control Systems segment produces hot runner and process control systems, along with maintenance, repair, and operating supplies for plastic processing equipment. The Fluid Technologies segment specializes in synthetic and semi-synthetic lubricants and coolants for industrial metalworking applications. With a diverse customer base exceeding 27,000, Milacron maintains strong market shares in North America and emerging markets like China and India.

MagicSchool

Series B in 2025
MagicSchool is a technology company that specializes in providing artificial intelligence-driven tools to support educators. Its comprehensive platform offers over 60 AI tools designed to assist teachers in various aspects of their profession, including lesson planning, assessment creation, differentiation, and communication. By generating original, tailored educational content, feedback, and recommendations, MagicSchool aims to enhance educators' productivity and effectiveness.

Archive

Series B in 2025
Archive is a technology company specializing in the development of customized resale programs that empower brands to manage their secondhand markets effectively. Collaborating with notable brands, Archive creates tailored resale experiences aimed at extending the lifecycle of clothing while generating additional revenue and enhancing customer loyalty. The company leverages advanced technology and design capabilities to offer flexible solutions that cater to the unique needs of each brand. Its platform supports various resale models, including peer-to-peer transactions, take-back programs, returns, and brand-owned inventory. By providing proprietary item intelligence software, Archive enables brands to establish comprehensive resale operations that maximize profitability and minimize environmental impact, facilitating the buying and selling of pre-owned fashion items at accessible prices.

Stripe-A-Zone

Acquisition in 2025
Founded in 1950, Stripe-A-Zone specializes in pavement marking services, including airport markings, parking lot striping, sealcoating, and maintenance. As of 2020, it operates under Frontline Road Safety, a company formed by Sterling Group.

Dhoot Transmission P

Private Equity Round in 2025
Dhoot Transmission Pvt. Ltd. is an Indian conglomerate specializing in the manufacture and provision of various automotive components, including wiring harnesses, electronic sensors, controllers, and automotive switches. The company also produces power cords and offers solutions for cable systems, copper wires, and tooling for electronics, stamping, and molding systems. With 23 manufacturing facilities worldwide, Dhoot Transmission serves a diverse customer base across eight countries and three continents. The company is ISO certified and has expanded its operations through strategic acquisitions within the industry. During the COVID-19 pandemic, Dhoot Transmission successfully resumed operations while adhering to health and safety guidelines.

Jamco

Acquisition in 2025
Jamco is a Japan-based company specializing in the manufacture of components for the aviation industry, particularly focusing on aircraft engines and interiors. The company operates through several business divisions, including Aircraft Interiors, Aircraft Seats, Aircraft Components, and Aircraft Maintenance. Its Aircraft Interiors division produces essential products such as galleys and lavatories for passenger aircraft, while the Aircraft Seats division specializes in the design and manufacture of passenger seating solutions. Additionally, the Aircraft Components division focuses on the production of critical equipment like heat exchangers. Jamco also provides maintenance services, ensuring that aircraft operate safely and comfortably. Through its innovative technologies, Jamco contributes significantly to enhancing the passenger experience in air travel.

Timberlyne Therapeutics

Series A in 2025
Timberlyne Therapeutics is a biopharmaceutical company focused on developing and commercializing innovative therapies for autoimmune diseases. It leverages its team's expertise in drug development to acquire promising assets targeting unmet medical needs. The company specializes in monoclonal antibodies with enhanced complement-dependent cytotoxicity, specifically targeting CD38, a protein highly expressed in various immune cells. This approach enables rapid and durable responses across a range of autoimmune diseases.

Cofactr

Series A in 2024
Cofactr, founded in 2021 by Matthew Haber and Phillip Gulley in New York, specializes in supply chain automation and procurement optimization for critical industries such as aerospace, defense, medtech, and robotics. The company offers an automated electronics purchasing assistant that aids hardware teams in sourcing necessary components by connecting them with global suppliers. Cofactr's platform features powerful supply chain intelligence, intuitive forecasting, transparent search capabilities, automated quoting, and instant purchasing. By streamlining these processes, Cofactr enables clients to proactively address sourcing challenges and reduce supply issues, ensuring the timely delivery of essential hardware.

Mayapada Hospital

Post in 2024
Mayapada Hospital offers health and hospital management services. They provide a range of services ranging from diagnosis, therapy, surgery, and rehabilitation to comprehensive care and control of neurological disorders. They offer clinical services and medical consultations for digestive tract problems. Their paediatric centre also provides physical check-ups, vaccinations, and treatment for specific paediatric symptoms, heart failure, and orthopaedic disorders.

Angitia Biopharmaceuticals

Series C in 2024
Angitia Biopharmaceuticals is a global biotechnology company dedicated to the discovery and development of innovative therapeutics targeting serious musculoskeletal diseases. The company specializes in researching and developing breakthrough therapies for conditions affecting bones, muscles, and joints. By focusing on creating novel drugs, Angitia aims to provide effective treatments that enhance patient recovery from severe musculoskeletal ailments.

Pollo Tropical

Debt Financing in 2024
Pollo Tropical has been committed to providing fresh, great-tasting dishes in its kitchens every day. Authentic preparation, fresh ingredients, and a creative touch on traditional flavors are the perfect mix for delicious, craveable food.

Wrightwell

Private Equity Round in 2024
Wrightwell operates as a services platform that offers customizable, institutional access to a multi-trillion-dollar asset class to investors of all types and sizes. The company's services are primarily focused on asset management, construction, financial services, and real estate. Vantage's Single Family Rental (SFR) Services, backed by proprietary technology, empower investors to make SFR a significant part of their portfolio. The company also assists clients in determining leasing criteria and guidelines, such as background checks, employment documentation, and credit score minimums.

Olema Oncology

Post in 2024
Olema Oncology is a preclinical biotechnology company dedicated to developing innovative therapies for the treatment and prevention of estrogen receptor-positive breast cancer. The company specializes in discovering and commercializing targeted treatments specifically designed for women's cancers. By leveraging its extensive understanding of endocrine-driven cancers, nuclear receptors, and mechanisms of acquired resistance, Olema aims to create compounds that surpass existing therapies. The company's focus is on transforming the standard of care for both pre- and post-menopausal women with cancer, with an emphasis on developing more effective and convenient treatment options. Olema's pipeline includes drug candidates such as OP-1250 and OP-3136, which have progressed through discovery and preclinical studies.

Oak Reinsurance

Seed Round in 2024
OAK Re is an international provider of reinsurance.

Halcyon

Series C in 2024
Halcyon is a cybersecurity company specializing in ransomware protection for enterprise clients. Its platform combines pre-execution detection, behavioral modeling, and deception techniques to provide layered security, resiliency, recovery, and isolation capabilities.

VISO TRUST

Venture Round in 2024
VISO Trust is a San Francisco-based company founded in 2016 that specializes in vendor security due diligence. The company has developed a platform that provides comprehensive and actionable information regarding vendor security risks. This platform enables decision-makers to conduct informed risk assessments and make sound security choices by streamlining the vendor review process. By delivering reliable data, VISO Trust assists enterprises in managing third-party security risks effectively and transparently, ultimately enhancing their overall cybersecurity posture.

Northflank

Series A in 2024
Northflank Ltd., founded in 2013 and based in London, United Kingdom, develops a next-generation cloud hosting platform that provides a self-service environment for developers to build, run, and scale applications. The company specializes in platform as a service through application programming interfaces, supporting various workloads and facilitating integration with multiple cloud providers. Northflank's automated development operations platform offers a suite of services, including continuous integration, delivery, deployment, and data processing. By enabling efficient deployment and management of applications, Northflank aims to reduce costs and enhance operational effectiveness for organizations leveraging cloud technology at scale.

Lean Technologies

Series B in 2024
Lean Technologies Limited is a FinTech startup founded in 2019 and based in Riyadh, Saudi Arabia. The company specializes in developing an application programming interface (API) platform that facilitates access to consumer financial data. Its API suite addresses the complexities of fragmented financial infrastructure, allowing businesses to easily access their customers' financial information and execute instant bank transfers. Lean Technologies aims to improve the accessibility, transparency, and functionality of financial data and payment systems, contributing to a more inclusive and interconnected financial ecosystem for both consumers and businesses.

AQ Compute

Acquisition in 2024
AQ Compute, established in 2020 and headquartered in Hamburg, Germany, specializes in providing customized compute capacities powered by clean energy. The company offers modular data center and colocation services, leveraging artificial intelligence technology to support various computer, storage, and GPU applications. AQ Compute's mission is to decarbonize the colocation and data center industry, enabling clients to build sustainable, zero-emissions data centers.

The Openwork Partnership

Private Equity Round in 2024
The Openwork Partnership provides financial advisory and planning services, including mortgage guidance, buy-to-let and equity release options, and assistance with personal finance, savings and investments, retirement planning, pensions, and inheritance planning.

Decagon

Series B in 2024
Decagon offers AI customer support agents designed for enterprises. It is trusted by leading companies and startups, their generative AI delivers exceptional customer experiences. It provides auto-resolve issues, streamlines workflows, assists agents and gains powerful insights with seamless integrations tailored for success.

EvenUp

Series D in 2024
EvenUp is a legal technology company that specializes in cloud-based and AI-driven solutions for managing personal injury cases. The company offers a platform that automates various aspects of legal practices, particularly in valuing personal injury claims. By leveraging its Claims Intelligence Platform, which is underpinned by extensive data records, EvenUp enhances the efficiency and effectiveness of legal case management. Its software employs machine learning and artificial intelligence to assess the worth of lawsuits, helping plaintiffs secure fair outcomes and avoid premature settlements or excessive debts. Additionally, the platform provides attorneys with valuable data to facilitate principled settlement negotiations.

Pallet

Series A in 2024
Pallet develops supply chain software that provides comprehensive visibility, automation, control, and optimization for end-to-end logistics. Its flagship product integrates a Transportation Management System (TMS) and Warehouse Management System (WMS), designed to streamline and enhance business operations.

Kailera Therapeutics

Series A in 2024
Kailera Therapeutics is a biotechnology company focused on developing innovative treatments for obesity and associated conditions. It specializes in injectable and oral GLP-1 (Glucagon-like peptide-1) therapies, aiming to provide patients with transformative health solutions.

T-Gaia

Acquisition in 2024
T-Gaia is a telecommunications company based in Japan that operates primarily in three segments: Mobile, Solution, and Settlement Services. The company engages in the sales and distribution of mobile phones and offers corporate customers various solution services, including brokerage services for fixed-line communication and broadband services. T-Gaia has a significant presence in the prepaid market, selling prepaid cards and codes, primarily through convenience stores, which have been steadily expanding. Additionally, the company provides a nationwide electronic payment system and distributes gift cards in Singapore through its subsidiaries.

Zenlytic

Series A in 2024
Zenlytic is a business intelligence platform that focuses on enhancing data accessibility and analysis for e-commerce businesses. Central to its offering is Zoë, an advanced data analyst chatbot that significantly streamlines the data request process, reducing ad hoc requests by over 80% and providing answers 1200 times faster than traditional data teams. Zenlytic's platform is designed as a no-code tool that automatically identifies critical changes in data, presents insights in a user-friendly manner, and allows for in-depth exploration of the factors influencing key metrics. By developing a unique LLM-native semantic layer and integrating it with a powerful AI agent, Zenlytic provides clients with a comprehensive understanding of their business through intuitive dashboards and advanced analytics, all communicated in plain English.

Serán Bioscience

Private Equity Round in 2024
Serán Bioscience is a contract development and manufacturing organization that specializes in providing a wide range of services to pharmaceutical and biotechnology companies. The company offers a comprehensive suite of development, analytical, and clinical manufacturing services, aimed at optimizing drug development and production processes. By catering to various aspects of pharmaceutical development, Serán Bioscience supports its clients in efficiently bringing their products to market.

Digital Media Solutions

Private Equity Round in 2024
Digital Media Solutions is a leading performance marketing company that leverages actionable data, insightful analytics, and proprietary technology to help clients reach, engage, and acquire customers across various interactive platforms. With a focus on precision targeting and customer acquisition, DMS caters to top brands in competitive industries, offering a range of performance marketing, digital agency services, and marketing technology solutions. Through meticulous execution and a suite of proprietary assets, Digital Media Solutions delivers effective marketing strategies to drive client success.

Mintlify

Series A in 2024
Mintlify empowers developers to create user-friendly public documentation. Trusted by over 7000 companies, its AI-native platform automatically generates documentation from code, saving time and improving user experience.

AutoComplete

Seed Round in 2024
AutoComplete, Inc. is an insurance-technology company headquartered in San Francisco, California. It focuses on integrating artificial intelligence at the point of sale, specifically targeting the substantial car insurance market valued at $311 billion. The company has developed an AI-driven platform that simplifies the process of obtaining auto protection, aiming to enhance the user experience by minimizing effort in securing automotive insurance. Through its innovative software, AutoComplete seeks to provide efficient solutions that redefine how consumers engage with auto insurance services.

Contextual AI

Series A in 2024
Contextual AI offers a pioneering approach to generative AI for the workplace.

Imperative Care

Series E in 2024
Imperative Care, Inc. is a medical technology company based in Campbell, California, established in 2015. The company specializes in developing innovative solutions aimed at enhancing the diagnosis, treatment, and rehabilitation of stroke patients. Its primary offerings include the Large Distal Platform, a catheter designed to facilitate access to treatment sites for both ischemic and hemorrhagic stroke procedures, and the ZOOM Aspiration System, which works in conjunction with the Large Distal Platform to provide a comprehensive solution for clot removal across various occlusion sizes. By focusing on improving the speed and effectiveness of acute stroke treatment, Imperative Care aims to address significant unmet needs in stroke care, ultimately providing patients with better prospects for recovery.

Somacis

Acquisition in 2024
Somacis SpA specializes in the manufacturing and supply of printed circuit boards (PCBs), including rigid, flex, and rigid-flex types. The company is recognized for its expertise in high-density interconnect (HDI) and flex-rigid PCBs, offering solutions that accommodate up to 50 layers. Somacis provides a range of products such as buried components, metal core solutions, RF/microwave products, graphic overlays, touch screens, and custom membrane switches. Founded in 1972 and headquartered in Castelfidardo, Italy, Somacis operates additional production facilities in Manfredonia, Italy; Poway, California; and Guangdong, China. The company serves various industries, including telecommunications, aerospace, defense, industrial, medical, automotive, and information technology, catering to both time-sensitive and mass production needs.

Kestra Medical Technologies

Private Equity Round in 2024
Kestra Medical Technologies, Inc. is a company that specializes in developing and manufacturing wearable medical devices aimed at monitoring and managing acute medical conditions. Founded in 2014 and headquartered in Kirkland, Washington, the company offers solutions that enable the collection, communication, and storage of patient performance data, facilitating both real-time and retrospective analysis. Among its key products are wearable cardioverter defibrillators designed to prevent sudden cardiac death and aid in the recovery of at-risk cardiac patients. By focusing on intuitive and mobile diagnostic and therapeutic technologies, Kestra Medical Technologies strives to enhance patient care and support healthcare teams in effectively managing patient health.

Momento

Series A in 2024
Momento was founded with the vision to enable developers to write reliable and powerful apps faster than ever thought possible. Momento removes the need to manage caches by providing a serverless caching solution that works at any scale, so developers can concentrate on doing what they love: developing better products and services, faster. Momento is a team of distributed systems and database experts. The company is headquartered out of Seattle, Washington with a team that is distributed worldwide. Visit gomomento.com for more information—or see just how fast and simple it is to get going with Momento by starting for free at start.gomomento.com.

MRO Holdings

Private Equity Round in 2024
MRO Holdings is a company that specializes in aircraft maintenance, modifications, and conversions, offering a comprehensive suite of technical solutions for the aviation industry. Its services encompass airframe maintenance, engineering, and the development of maintenance programs and reliability strategies. By focusing on long-term applications within the aircraft maintenance sector, MRO Holdings aims to create a stable and challenging work environment for aviation professionals, emphasizing a strong culture of safety, quality, and performance.

Savara Pharmaceuticals

Post in 2024
Savara is an orphan lung disease company. Savara’s pipeline comprises Molgradex, an inhaled granulocyte-macrophage colony-stimulating factor, or GM-CSF, in Phase 3 development for autoimmune pulmonary alveolar proteinosis, or aPAP, in Phase 2a development for nontuberculous mycobacteria, or NTM, lung infection, and in preparation for Phase 2a development in cystic fibrosis, or CF, affected individuals with chronic NTM lung infection; and AeroVanc, a Phase 3 stage inhaled vancomycin for treatment of persistent methicillin resistant staphylococcus aureus, or MRSA, lung infection in CF. Savara’s strategy involves expanding its pipeline of potentially best-in-class products through indication expansion, strategic development partnerships and product acquisitions, with the goal of becoming a leading company in its field. The most recent acquisition is aerosolized amikacin/fosfomycin, a Phase 2 ready, proprietary combination antibiotic, which has demonstrated potent and broad-spectrum antibacterial activity against highly drug resistant pathogens. Savara’s management team has significant experience in orphan drug development and pulmonary medicine, identifying unmet needs, developing and acquiring new product candidates, and effectively advancing them to approvals and commercialization.

Pomerium

Series A in 2024
Pomerium is a developer of identity-aware proxy software that enhances security by providing controlled access to internal applications without the need for a virtual private network (VPN). The company's software offers a standardized interface that facilitates user authentication, authorization, and monitoring for any application, allowing enterprises to secure access to both internal and external applications. By streamlining access control processes, Pomerium enables developers to concentrate on their applications without the burden of reinventing access management solutions.

Bapcor

Private Equity Round in 2024
Bapcor is a leading provider of automotive aftermarket parts, accessories, and services in Australasia, primarily operating in Australia and New Zealand. The company specializes in the distribution of automotive spare parts through its Trade, Retail & Service, and Specialist Wholesale segments. Its Trade businesses include Burson Auto Parts and BNT, which offer a vast selection of car parts for over 400 vehicle makes and models. In the Retail & Service sector, Bapcor operates brands such as Autobarn, Autopro, and Sprint Auto Parts, catering to the do-it-yourself market, as well as service-oriented businesses like Midas and ABS. Additionally, its Specialist Wholesale segment focuses on providing specialized automotive parts. Through these diverse offerings, Bapcor serves both independent and chain mechanic workshops, establishing itself as a significant player in the automotive aftermarket industry.

Cube Dev

Series B in 2024
Cube Dev provides an open-source analytical API platform that enables internal business intelligence and customer-facing analytics through a semantic layer. The semantic layer unifies business logic, centralizes governance and security, and optimizes query performance, while supporting integration with any data endpoint. Cube Cloud offers a managed infrastructure with query inspection and tracing, monitoring, and pre-aggregation management. The platform includes visualization-agnostic tools for building user interfaces and analytical APIs, and supports modern data stores to handle large data volumes with built-in security. Cube Dev serves organizations seeking scalable, governed analytics applications.

CereVasc

Series B in 2024
CereVasc, Inc. is a medical device company based in Auburndale, Massachusetts, specializing in the development of innovative, minimally invasive treatments for neurological diseases. The company has created the eShunt System, an endovascularly deliverable cerebrospinal fluid (CSF) shunt designed to replace traditional surgical methods for treating communicating hydrocephalus. This system aims to eliminate the need for invasive surgery, general anesthesia, and hospitalization, which are typically associated with the conventional use of ventriculo-peritoneal shunts. By providing a less invasive alternative, CereVasc seeks to improve patient outcomes and reduce the overall costs related to the surgical management of life-threatening neurological conditions. Established in 2014, CereVasc is focused on advancing healthcare solutions that enhance the treatment of various neurological brain disorders.

Sikich

Private Equity Round in 2024
Sikich is a Chicago-based accounting firm established in 1982 that provides a wide range of services, including accounting, auditing, tax planning, and information technology managed services. The firm also has a dedicated investment banking division that specializes in mergers and acquisitions, as well as capital raising for corporations, private equity firms, and entrepreneurs. Sikich serves various sectors, including healthcare and life sciences, agriculture, construction, manufacturing, technology, education, and retail, offering tailored financial and strategic advisory services to meet the unique needs of its clients.

Ansa

Series A in 2024
Ansa is a technology company that specializes in developing a closed-loop payment platform aimed at enhancing customer loyalty for businesses. Its innovative technology enables marketers to create customer balances, load funds, and gain valuable insights into consumer spending habits. By financing customer accounts, Ansa's platform helps businesses reduce payment costs, increase transaction values, and foster repeat transactions. This approach supports brands in retaining and rewarding loyal customers, ultimately driving growth and profitability.

Prophet Security

Seed Round in 2024
Prophet Security provides security operations by automating the triage, investigation, and response process.

Century Therapeutics

Post in 2024
Century Therapeutics, Inc. is a biotechnology company focused on developing innovative cell therapies derived from induced pluripotent stem cells (iPSCs) to treat hematologic and solid malignancies. Founded in 2018 and headquartered in Philadelphia, Pennsylvania, the company utilizes a specialized platform that integrates gene editing and protein engineering to create allogeneic therapies. This platform allows for the generation of master cell banks of modified immune effector cells, specifically engineered to optimize performance and reduce the risk of rejection by the host immune system. By employing advanced technologies such as CRISPR-mediated gene editing and proprietary chimeric antigen receptors, Century Therapeutics aims to address significant unmet medical needs in cancer and other diseases.

Homebase

Series D in 2024
Homebase is a developer of employee management software focused on simplifying the administrative tasks associated with hourly work. The platform offers tools for scheduling, time tracking, and communication, all designed to minimize the burden on employers and employees alike. Its cloud-based system allows users to manage timesheets and track hours from any location, facilitating efficient payroll preparation. While the basic features are available for free, Homebase also provides tiered pricing options for businesses seeking additional functionalities. By streamlining these processes, Homebase aims to help organizations save time and improve coordination among their teams.

Xilio Therapeutics

Post in 2024
Xilio Therapeutics is a clinical-stage biotechnology company focused on developing innovative immunotherapies to enhance the immune system's ability to combat cancer. The company specializes in tumor-selective immunotherapies, utilizing its proprietary technology to maximize the effectiveness of immuno-oncology treatments while minimizing side effects outside the tumor. Among its key products is XTX201, which aims to induce immune activity directly within tumors, demonstrating improved antitumor effects. Founded in 2015 and based in Waltham, Massachusetts, Xilio Therapeutics was previously known as Akrevia Therapeutics until its rebranding in March 2020. The company is dedicated to advancing a pipeline of novel immuno-oncology molecules, including tumor-activated cytokines and antibodies, with the goal of significantly improving patient outcomes in cancer treatment.

Gather AI

Series A in 2024
Gather AI is an autonomous inventory management platform that specializes in providing inventory as a service for modern warehouses. Founded in 2017 and headquartered in Pittsburgh, Pennsylvania, the company offers a comprehensive solution that combines its proprietary software with off-the-shelf drones, allowing businesses to automate inventory tasks effectively. The software is designed to operate safely in environments without GPS, utilizing artificial intelligence to facilitate data analytics and inventory monitoring. With a team of PhDs and research engineers from the Carnegie Mellon Robotics Institute, Gather AI aims to enhance operational efficiency for its clients by enabling seamless inventory management and monitoring.

Loyal

Series B in 2024
Loyal is a biotechnology company focused on developing veterinary pharmaceuticals aimed at extending the health span and lifespan of dogs. The company creates medicines designed to delay the onset of age-related diseases such as cancer, heart disease, and metabolic disorders. By quantifying and regulating the aging process, Loyal seeks to mitigate the effects of aging, thereby promoting healthier and longer lives for dogs. Through its innovative approach, the company aspires to improve the quality of life for pets and enhance their longevity.

Unstructured

Series B in 2024
Unstructured is a developer of an open-source data transformation platform that simplifies the process of converting raw data, such as PDFs and Microsoft Office documents, into formats compatible with language models. The platform supports over 25 file types, including PDF, DOC, and PPTX, and offers connectors to various systems like SharePoint, S3, and Databricks. By facilitating effortless data extraction and integration into AI workflows, Unstructured enhances the accessibility of human-generated information, ensuring that it is readily available for generative AI systems. Its modular architecture allows users to incorporate any third-party model, making it a versatile solution for preprocessing natural language data for machine learning applications.

Fermat Commerce

Series A in 2024
Fermat Commerce operates an influencer-driven e-commerce platform designed to enhance brand sales and provide a seamless shopping experience for end-users. The platform enables content creators to embed brand-direct shopping features on their websites, allowing customers to purchase products without leaving the creators' content. By offering e-commerce enablement software, Fermat Commerce supports both merchants and content creators in building and managing their online stores, thereby facilitating a direct connection between brands and consumers within a creator's online environment.

Argyle

Series C in 2024
Argyle develops a payroll connectivity platform that enables businesses to automate income and employment verifications securely. This platform allows service providers in industries like mortgage, personal lending, tenant screening, and gig economy to streamline verification processes, reduce risks, and lower costs.

Relay

Series B in 2024
Relay is an-all-in-one, collaborative business banking and money management platform that helps small businesses and their teams take control of their cash flow and get crystal clear on what they’re earning, spending and saving. With Relay, business owners can: -Bank with no monthly account fees, no overdraft fees, and no minimum balance required -Organize income, expenses and cash reserves using up to 20 individual accounts -2 savings accounts offering between 1-3% APY -Issue up to 50 virtual or physical Visa® debit cards to meticulously organize spending by team or project -Send payments and deposits via ACH, wires or checks -Cashflow automations, like maximum balance transfer rules and recurring payments -Give team members and financial advisors secure, role-based banking access -Integrate banking with accounting softwares like QuickBooks Online and Xero -Get personalized customer support by email and phone Relay is also the official banking partner of Profit First, the cash flow management methodology and book created by serial entrepreneur Mike Michalowicz.

GigEasy

Pre Seed Round in 2024
GigEasy is a technology company developing an insurance and benefits platform tailored to the gig economy. Its platform offers flexible coverage options, including health, dental, and vision plans, with on-demand activation and competitive pricing. GigEasy's API enables businesses to integrate insurance directly into their platforms, allowing gig workers to safeguard their income and businesses to provide attractive benefits packages.

Areteia Therapeutics

Series A in 2024
Areteia Therapeutics is a biotechnology company focused on developing oral therapies for eosinophilic asthma to improve disease control. The company was spun out of Knopp and is advancing an oral drug designed to inhibit eosinophil maturation, aiming to reduce inflammation and alleviate symptoms of severe asthma. Phase 2 data from its program indicated the oral candidate lowers blood eosinophil counts, a marker associated with better lung function. By pursuing an oral, non-injectable treatment option, Areteia seeks to offer a convenient alternative to injectable therapies and broaden access for asthma patients. The company’s work centers on targeting eosinophil-related pathways to enhance asthma management and patient quality of life.

Navro

Venture Round in 2024
Navro is a fintech platform that provides payment and banking infrastructure for software companies to scale their operations globally. It offers a regulated network that curates payment options, enables checkout in preferred methods, connects various payment acceptance methods, collects funds locally, and provides payment stack management with real-time local coverage, supporting international growth while maintaining regulatory compliance.

Branching Minds

Private Equity Round in 2024
Branching Minds, Inc. is a New York-based company that offers a web-based platform designed to assist educators and parents in identifying and addressing students' learning challenges. Incorporated in 2013, the company provides tools that facilitate the collection of data on observable student behaviors through a structured Q&A process. This allows educators to pinpoint cognitive issues and strengths effectively. The platform further enhances the educational process by algorithmically matching identified challenges with research-backed supports, thereby enabling personalized interventions. Additionally, it equips learning specialists, psychologists, and special educators with the ability to track observations, systematize record-keeping, and generate reports on student progress, ultimately improving the response to intervention and multi-tier systems of support in educational settings.

Accolade Wines

Acquisition in 2024
Accolade Wines is a global wine business based in South Australia. It is the leading wine company in Australia and the United Kingdom by volume and the fifth largest in the world, with a heritage dating to 1853 and a portfolio of well-known brands.

Solid Biosciences

Post in 2024
Solid Biosciences Inc. is a life science company focused on developing therapies for Duchenne muscular dystrophy (DMD), a genetic muscle-wasting disease primarily affecting boys. The company's lead product candidate, SGT-001, is a gene transfer therapy currently undergoing a Phase I/II clinical trial aimed at restoring functional dystrophin protein expression in patients' muscles. In addition to SGT-001, Solid Biosciences is advancing the Anti-LTBP4 program, which involves a monoclonal antibody designed to reduce fibrosis and inflammation by targeting the LTBP4 protein. The company also develops biomarkers and sensors, as well as the Solid Suit program, which focuses on creating wearable assistive devices with functional and therapeutic benefits. Founded in 2013 and headquartered in Cambridge, Massachusetts, Solid Biosciences has established a strategic collaboration with Ultragenyx to enhance gene therapy development for DMD. With no current cure for DMD, the company aims to provide innovative solutions for a condition that affects an estimated 10,000 to 15,000 cases in the United States.

Avistone Pharmaceuticals

Series B in 2023
Avistone Pharmaceuticals is a clinical-stage biotechnology company focused on precision oncology therapeutics.

Halcyon

Series B in 2023
Halcyon is a cybersecurity company specializing in ransomware protection for enterprise clients. Its platform combines pre-execution detection, behavioral modeling, and deception techniques to provide layered security, resiliency, recovery, and isolation capabilities.

Syros Pharmaceuticals

Post in 2023
Syros Pharmaceuticals, Inc. is a biopharmaceutical company based in Cambridge, Massachusetts, that specializes in developing innovative treatments for cancer and monogenic diseases through gene control medicines. The company is advancing its lead product candidates, including SY-1425, a selective retinoic acid receptor alpha agonist currently in Phase II clinical trials for specific patient populations with acute myeloid leukemia and myelodysplastic syndrome, and SY-5609, a cyclin-dependent kinase 7 inhibitor under investigation in a Phase I clinical trial for advanced solid tumors. Syros is also engaged in collaborative research, including a partnership with Incyte Corporation aimed at identifying therapeutic targets for myeloproliferative neoplasms and a licensing agreement with TMRC Co. Ltd. for the development of tamibarotene. With a focus on mapping gene regulatory circuits, Syros leverages its proprietary platform and expertise to address significant unmet medical needs in oncology. Founded in 2011, the company aims to establish new standards of care for patients with hematologic malignancies.

1440 Foods

Acquisition in 2023
1440 Foods develops and markets sports and active nutrition brands focused on protein and nutrition supplements. Its portfolio includes health and wellness brands, protein powders, meal replacements and lifestyle brands that support balanced nutrition and healthier living.

Andalusia Labs

Series A in 2023
Andalusia Labs is focused on creating foundational digital infrastructure tailored for internet markets, particularly in the realm of digital assets. The company develops a comprehensive risk management infrastructure that includes a security platform and a risk management marketplace. This infrastructure is designed to assist the blockchain market in effectively managing substantial amounts of digital assets, thereby supporting innovative companies worldwide. Through its offerings, Andalusia Labs aims to enhance the security and stability of digital asset transactions and management.

Eleda Group

Acquisition in 2023
Eleda Group specializes in engineering, excavation, and construction services focused on critical infrastructure sectors, including water, heating, and transportation. The company provides a wide range of services, from complete project contracts to machinery leasing. Its expertise extends to building and maintaining the electricity grid, as well as developing hydro and wind power plants, which are essential for supporting the electrification and digitalization of society. Eleda operates through local companies that are leaders in their respective markets, enabling them to handle projects of various scales, from smaller assignments to comprehensive contracts.

MaintainX

Series C in 2023
MaintainX is a software-as-a-service platform that digitizes work orders and procedures for frontline and maintenance teams. The platform supports workflow digitization, collaboration, and analytics, along with environmental and training checklists, tooling and gauge reporting, auditing and inspection workflows, and quality control inspections, with capabilities to communicate and upload photos. It helps manufacturing facilities, restaurants, hotels, and other business groups streamline maintenance operations, manage asset information, and support regulatory compliance and audits. The solution emphasizes IoT-enabled features and real-time field insights to improve efficiency and reliability in maintenance, reliability, and operations. Founded in 2018 and headquartered in San Francisco, California, MaintainX provides a mobile-first platform designed to empower frontline workers with a modern digital workflow.

Eyebiotech

Series A in 2023
Eyebiotech is a vision treatment company that develops products to preserve, repair, and improve eyesight. The firm guards against sight-threatening eye disorders and developed the first anti-vascular endothelial growth factor medication for patients with age-related macular degeneration, allowing those with eye ailments to regain their eyesight.

Gynesonics

Venture Round in 2023
Gynesonics, Inc. is a medical device company focused on developing innovative solutions for women's health, specifically addressing symptomatic uterine fibroids. Founded in 2005 and headquartered in Redwood City, California, with an additional location in Beuningen, the Netherlands, Gynesonics offers the Sonata System, a minimally invasive treatment that utilizes sonography guidance for the transcervical ablation of fibroids. This incision-free approach provides a safe and effective alternative to traditional surgical methods such as hysterectomy or myomectomy, aiming to alleviate severe menstrual symptoms associated with fibroids. Gynesonics is dedicated to improving the quality of care for women by offering advanced technologies that enhance treatment options in gynecology.

Aiolos Bio

Series A in 2023
Aiolos Bio is a biotechnology company specializing in the development of therapies for respiratory diseases and immune conditions. Its primary focus is on advancing AIO-001, a monoclonal antibody therapy for moderate-to-severe asthma, designed for dosing every 6 months. The company, founded by industry veterans, aims to address unmet treatment needs and improve patient outcomes by providing more efficacious and less burdensome therapies.

Aleph

Series A in 2023
Aleph operates a financial planning and analysis platform designed to enhance the capabilities of traditional spreadsheets such as Excel and Google Sheets. By integrating data from accounting systems and various operational sources, Aleph provides specialized financial tools that are always current. This allows clients to create sophisticated financial models and use cases, ultimately facilitating informed investment decisions. Aleph aims to support finance departments by merging the familiarity of spreadsheets with advanced financial insights, making it a valuable resource for financial professionals.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.